News
Blueprint's mastocytosis drug Ayvakit cleared for NHS use
NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis (ASM) by the NHS in England and Wales, including firs
